The Management of Upper-Extremity Xylazine-Associated Wounds

Area of Science:

• Public Health
• Infectious Diseases
• Wound Care

Background:

• Xylazine (an animal tranquilizer) is increasingly detected in the illicit drug supply.
• Necrotic soft tissue wounds associated with xylazine use pose a significant burden on healthcare systems.
• This study analyzes the initial experience with xylazine-associated wounds in Philadelphia.

Purpose of the Study:

• To analyze the characteristics, treatments, and outcomes of patients with xylazine-associated wounds.
• To guide future treatment strategies and research directions for this emerging public health issue.

Main Methods:

• Retrospective review of 55 patients with self-reported xylazine use and upper-extremity wounds.
• Analysis of patient demographics, comorbidities, treatments, and hospital outcomes.
• Study design: Therapeutic study IV.

Main Results:

• High prevalence of homelessness (40%), psychiatric diagnoses (26%), and tobacco use (84%) among affected patients.
• High rates of hospital readmissions (median 3 per patient) and leaving against medical advice (AMA) (49%).
• Surgical intervention had a 59% complication rate; 60% of patients received nonoperative wound care.

Conclusions:

• Xylazine-associated wounds are linked to complex patient factors including homelessness, psychiatric conditions, and substance use, complicating management.
• These factors contribute to high complication rates in surgical patients and frequent AMA discharges.
• Effective treatment requires addressing underlying social determinants of health and substance use patterns.